Related references
Note: Only part of the references are listed.Antimicrobial Resistance Following Azithromycin Mass Drug Administration: Potential Surveillance Strategies to Assess Public Health Impact
Ines Mack et al.
CLINICAL INFECTIOUS DISEASES (2020)
Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies
Mark Jit et al.
BMC MEDICINE (2020)
Azithromycin resistant gonococci: a literature review
Awoke Derbie et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2020)
Antibiotic stewardship in community-acquired pneumonia
Diego Viasus et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2017)
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point
Thomas M. File et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis
Khalid Eljaaly et al.
BMC INFECTIOUS DISEASES (2017)
Macrolide therapy of pneumonia: is it necessary, and how does it help?
Marcos I. Restrepo et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2016)
Macrolide Antibiotics and the Risk of Cardiac Arrhythmias
Richard K. Albert et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Use of Azithromycin and Death from Cardiovascular Causes
Henrik Svanstrom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports
Jules C. Hancox et al.
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE (2013)
Azithromycin and the Risk of Cardiovascular Death
Charles A. Knirsch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis
Christophe Marti et al.
CRITICAL CARE (2012)
Azithromycin and the Risk of Cardiovascular Death
Wayne A. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The etiology of community-acquired pneumonia in Australia: Why penicillin plus doxycycline or a macrolide is the most appropriate therapy
Patrick G. P. Charles et al.
CLINICAL INFECTIOUS DISEASES (2008)
Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial
Jan Jelrik Oosterheert et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae
Miika Bergman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Share Paper
